NO20034291D0 - 2-aminopropanolderivater - Google Patents
2-aminopropanolderivaterInfo
- Publication number
- NO20034291D0 NO20034291D0 NO20034291A NO20034291A NO20034291D0 NO 20034291 D0 NO20034291 D0 NO 20034291D0 NO 20034291 A NO20034291 A NO 20034291A NO 20034291 A NO20034291 A NO 20034291A NO 20034291 D0 NO20034291 D0 NO 20034291D0
- Authority
- NO
- Norway
- Prior art keywords
- sub
- aminopropanol derivatives
- compounds
- aminopropanol
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
- C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0107507A GB0107507D0 (en) | 2001-03-26 | 2001-03-26 | Organic compounds |
GB0107506A GB0107506D0 (en) | 2001-03-26 | 2001-03-26 | Organic compounds |
GB0108346A GB0108346D0 (en) | 2001-04-03 | 2001-04-03 | Organic compounds |
PCT/EP2002/003389 WO2002076995A2 (en) | 2001-03-26 | 2002-03-26 | 2-amino-propanol derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20034291D0 true NO20034291D0 (no) | 2003-09-25 |
NO20034291L NO20034291L (no) | 2003-11-24 |
Family
ID=27256123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20034291A NO20034291L (no) | 2001-03-26 | 2003-09-25 | 2-aminopropanolderivater |
Country Status (18)
Country | Link |
---|---|
US (1) | US7326801B2 (no) |
EP (1) | EP1377593B1 (no) |
JP (1) | JP4012823B2 (no) |
KR (1) | KR20030093279A (no) |
CN (1) | CN1620461A (no) |
AT (1) | ATE314383T1 (no) |
BR (1) | BR0208365A (no) |
CA (1) | CA2442178A1 (no) |
CZ (1) | CZ20032560A3 (no) |
DE (1) | DE60208355T2 (no) |
DK (1) | DK1377593T3 (no) |
ES (1) | ES2254675T3 (no) |
IL (1) | IL157773A0 (no) |
MX (1) | MXPA03008755A (no) |
NO (1) | NO20034291L (no) |
PL (1) | PL367348A1 (no) |
SK (1) | SK11942003A3 (no) |
WO (1) | WO2002076995A2 (no) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04006709A (es) | 2002-01-11 | 2004-10-04 | Sankyo Co | Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen. |
JP5227492B2 (ja) | 2002-05-16 | 2013-07-03 | ノバルティス アーゲー | 癌におけるedgレセプター結合剤の使用 |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
WO2004010949A2 (en) | 2002-07-30 | 2004-02-05 | University Of Virginia Patent Foundation | Compounds active in spinigosine 1-phosphate signaling |
WO2004024673A1 (en) * | 2002-09-13 | 2004-03-25 | Novartis Ag | Amino-propanol derivatives |
WO2004026817A1 (ja) * | 2002-09-19 | 2004-04-01 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
JP4509028B2 (ja) | 2002-09-24 | 2010-07-21 | ノバルティス アーゲー | 有機化合物 |
WO2004071442A2 (en) * | 2003-02-11 | 2004-08-26 | Irm Llc | Novel bicyclic compounds and compositions |
AU2004213297B2 (en) | 2003-02-18 | 2009-03-19 | Kyorin Pharmaceutical Co., Ltd. | Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators |
SI2316431T1 (sl) | 2003-04-08 | 2016-04-29 | Novartis Ag | Trdna sestava za oralno odmerjanje, ki vsebuje agonista receptorja S1P in sladkorni alkohol |
WO2004096757A1 (en) * | 2003-04-30 | 2004-11-11 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
EP1622860B1 (en) * | 2003-04-30 | 2012-02-29 | Novartis AG | AMINO-PROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORs |
GB0313612D0 (en) * | 2003-06-12 | 2003-07-16 | Novartis Ag | Organic compounds |
WO2005021503A1 (en) * | 2003-08-28 | 2005-03-10 | Novartis Ag | Aminopropanol derivatives |
GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
US7638637B2 (en) | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
WO2005044780A1 (ja) * | 2003-11-10 | 2005-05-19 | Kyorin Pharmaceutical Co., Ltd. | アミノカルボン酸誘導体とその付加塩及びs1p受容体調節剤 |
GB0329498D0 (en) * | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
US7910617B2 (en) | 2004-02-24 | 2011-03-22 | Sankyo Company, Limited | Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound |
GB0405289D0 (en) * | 2004-03-09 | 2004-04-21 | Novartis Ag | Organic compounds |
JP2007536310A (ja) | 2004-05-03 | 2007-12-13 | ノバルティス アクチエンゲゼルシャフト | S1p受容体アゴニストおよびjak3キナーゼ阻害剤を含む、組合せ剤 |
GB0411929D0 (en) | 2004-05-27 | 2004-06-30 | Novartis Ag | Organic compounds |
PL1772145T3 (pl) * | 2004-07-16 | 2011-08-31 | Kyorin Seiyaku Kk | Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym |
WO2006010630A1 (en) | 2004-07-30 | 2006-02-02 | Novartis Ag | Compound formulations of 2-amino-1, 3-propanediol compounds |
US7241812B2 (en) | 2004-08-13 | 2007-07-10 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
PT2511262T (pt) * | 2004-10-12 | 2017-03-30 | Kyorin Seiyaku Kk | Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol |
KR20070085465A (ko) | 2004-11-29 | 2007-08-27 | 노파르티스 아게 | S1p 수용체 효능제의 투여 용법 |
AU2006214314B2 (en) | 2005-02-14 | 2012-02-09 | University Of Virginia Patent Foundation | Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups |
GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
KR20080050591A (ko) | 2005-09-01 | 2008-06-09 | 아레스 트레이딩 에스.에이. | 시신경염 치료 |
KR101297302B1 (ko) * | 2005-10-07 | 2013-08-19 | 교린 세이야꾸 가부시키 가이샤 | 2-아미노-1,3-프로판디올 유도체를 유효성분으로 하는간장질환 치료제 및 간장질환 치료방법 |
RU2433117C2 (ru) * | 2005-12-15 | 2011-11-10 | Мицубиси Танабе Фарма Корпорейшн | Аминное соединение и его применение в медицинских целях |
EP1986623A2 (en) | 2006-01-27 | 2008-11-05 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
EP1987013A1 (en) | 2006-02-09 | 2008-11-05 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
MX2008013119A (es) | 2006-04-11 | 2008-10-21 | Novartis Ag | Inhibidores de hcv/vih y sus usos. |
WO2008018427A1 (fr) * | 2006-08-08 | 2008-02-14 | Kyorin Pharmaceutical Co., Ltd. | Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif |
EP2053038B1 (en) | 2006-08-08 | 2016-10-05 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative and immunosuppressive agent having same as an active ingredient |
NZ576893A (en) | 2006-11-21 | 2012-01-12 | Univ Virginia Patent Found | Tetralin analogs having sphingosine 1-phosphate agonist activity |
WO2008064320A2 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
AU2007323557A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
JP5341754B2 (ja) | 2007-06-14 | 2013-11-13 | 田辺三菱製薬株式会社 | アミン化合物及びその医薬用途 |
JP5452237B2 (ja) * | 2008-02-07 | 2014-03-26 | 杏林製薬株式会社 | アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤 |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US9011833B2 (en) | 2010-10-08 | 2015-04-21 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
GB201715786D0 (en) | 2017-09-29 | 2017-11-15 | Univ College Cardiff Consultants Ltd | Compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604229A (en) | 1992-10-21 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
ES2065855B1 (es) * | 1993-05-31 | 1995-09-01 | Menarini Lab | Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos. |
KR100358922B1 (ko) * | 1994-08-22 | 2003-01-24 | 미쯔비시 웰 파마 가부시키가이샤 | 벤젠화합물및그의의약으로서의용도 |
EP1319651B1 (en) * | 1997-04-04 | 2005-06-29 | Mitsubishi Pharma Corporation | 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor |
CN1267429C (zh) | 2000-07-13 | 2006-08-02 | 三共株式会社 | 氨基醇衍生物 |
AU8533101A (en) * | 2000-08-31 | 2002-03-13 | Merck & Co Inc | Phosphate derivatives as immunoregulatory agents |
-
2002
- 2002-03-26 US US10/472,127 patent/US7326801B2/en not_active Expired - Fee Related
- 2002-03-26 AT AT02727484T patent/ATE314383T1/de active
- 2002-03-26 DE DE60208355T patent/DE60208355T2/de not_active Expired - Lifetime
- 2002-03-26 CA CA002442178A patent/CA2442178A1/en not_active Abandoned
- 2002-03-26 WO PCT/EP2002/003389 patent/WO2002076995A2/en active IP Right Grant
- 2002-03-26 CZ CZ20032560A patent/CZ20032560A3/cs unknown
- 2002-03-26 SK SK1194-2003A patent/SK11942003A3/sk unknown
- 2002-03-26 BR BR0208365-5A patent/BR0208365A/pt not_active Application Discontinuation
- 2002-03-26 JP JP2002576253A patent/JP4012823B2/ja not_active Expired - Fee Related
- 2002-03-26 ES ES02727484T patent/ES2254675T3/es not_active Expired - Lifetime
- 2002-03-26 DK DK02727484T patent/DK1377593T3/da active
- 2002-03-26 PL PL02367348A patent/PL367348A1/xx not_active Application Discontinuation
- 2002-03-26 IL IL15777302A patent/IL157773A0/xx unknown
- 2002-03-26 MX MXPA03008755A patent/MXPA03008755A/es unknown
- 2002-03-26 CN CNA028068378A patent/CN1620461A/zh active Pending
- 2002-03-26 KR KR10-2003-7012474A patent/KR20030093279A/ko not_active Application Discontinuation
- 2002-03-26 EP EP02727484A patent/EP1377593B1/en not_active Expired - Lifetime
-
2003
- 2003-09-25 NO NO20034291A patent/NO20034291L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2004531501A (ja) | 2004-10-14 |
EP1377593A2 (en) | 2004-01-07 |
EP1377593B1 (en) | 2005-12-28 |
US20040147490A1 (en) | 2004-07-29 |
DK1377593T3 (da) | 2006-04-10 |
CN1620461A (zh) | 2005-05-25 |
DE60208355D1 (de) | 2006-02-02 |
ES2254675T3 (es) | 2006-06-16 |
WO2002076995A3 (en) | 2003-02-13 |
KR20030093279A (ko) | 2003-12-06 |
CZ20032560A3 (cs) | 2003-12-17 |
MXPA03008755A (es) | 2004-02-18 |
BR0208365A (pt) | 2004-03-09 |
JP4012823B2 (ja) | 2007-11-21 |
US7326801B2 (en) | 2008-02-05 |
NO20034291L (no) | 2003-11-24 |
SK11942003A3 (sk) | 2004-03-02 |
DE60208355T2 (de) | 2006-07-27 |
IL157773A0 (en) | 2004-03-28 |
WO2002076995A2 (en) | 2002-10-03 |
PL367348A1 (en) | 2005-02-21 |
ATE314383T1 (de) | 2006-01-15 |
CA2442178A1 (en) | 2002-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20034291D0 (no) | 2-aminopropanolderivater | |
ATE270817T1 (de) | Fungizide | |
NO20062644L (no) | DPP-IV inhibitorer | |
WO2003006425A3 (en) | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | |
MY136141A (en) | Novel hydantoin derivatives and pharmaceutical compositions useful as metalloproteinase inhibitors | |
DE60236102D1 (en) | 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren | |
SE0004245D0 (sv) | Novel compounds and their use | |
GEP20074198B (en) | N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials | |
DE60003863D1 (de) | Dioxocyclopentylhydroxamsäure | |
BR0209149A (pt) | Ftalazinonas | |
DE60127845D1 (de) | Benzylidenthiazolidindione und ihre verwendung als antimykotische mittel | |
MY133969A (en) | Indoloquinazolinones | |
DE60221508D1 (de) | Aminosäurederivate als hiv-protease-inhibitoren | |
TR200201128T2 (tr) | PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri. | |
SE9903290D0 (sv) | Novel compounds | |
BR0211903A (pt) | Isoxazolopiridinonas | |
BR0115996A (pt) | Sulfamidotienopirimidinas | |
DE60216948D1 (en) | 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren | |
DE60139770D1 (de) | Hydantoin derivate mit affinität für somatostatin rezeptoren | |
DE60043228D1 (de) | Herstellungsverfahren von 2-cyanopyridinen | |
ECSP045086A (es) | Composiciones farmaceuticas que contienen macrolidos | |
DE60236729D1 (de) | Aroma- und duftstoffzusammensetzungen | |
ATE364594T1 (de) | (4-acylaminopiperidin-1-yl)acetamide als neurokininantagonisten | |
DE60111956D1 (de) | Cyclophilin-bindende ligande | |
ECSP034778A (es) | Derivados de 2-amino-propanol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |